Evidence map›Paper›PMID 40230841›Full record

ArticleFrontiers in immunology2025

Design and development of highly conserved, HLA-promiscuous T cell multiepitope vaccines against human visceral leishmaniasis.

Aline Silva Barreto, Mariana Nobre Farias de Franca, Tatiana Leão Dos Santos Dos Reis, Joao Antonio Barbosa Martins Silva, Priscila Lima Dos Santos, Fabrícia Alvisi de Oliveira, Angela Maria da Silva, Lucas Sousa Magalhaes, Danielle Angst Secco, Maria Aiza Fontes Andrade and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Aline Silva BarretoMolecular Biology Laboratory, University Hospital, Department of Medicine Federal University of Sergipe, Aracaju, Sergipe, Brazil.
Mariana Nobre Farias de FrancaPostgraduate Program in Health Science, Federal University of Sergipe, Aracaju, SE, Brazil.
Tatiana Leão Dos Santos Dos ReisInstitute of Microbiology Paulo de Góes, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil.
Joao Antonio Barbosa Martins SilvaInstitute of Microbiology Paulo de Góes, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil.
Priscila Lima Dos SantosMolecular Biology Laboratory, University Hospital, Department of Medicine Federal University of Sergipe, Aracaju, Sergipe, Brazil.
Fabrícia Alvisi de OliveiraMolecular Biology Laboratory, University Hospital, Department of Medicine Federal University of Sergipe, Aracaju, Sergipe, Brazil.
Angela Maria da SilvaPostgraduate Program in Health Science, Federal University of Sergipe, Aracaju, SE, Brazil.
Lucas Sousa MagalhaesMolecular Biology Laboratory, University Hospital, Department of Medicine Federal University of Sergipe, Aracaju, Sergipe, Brazil.
Danielle Angst SeccoTIXUS Technologic Core for Tissue Repair and Histocompatibility, Rio de Janeiro State University, Rio de Janeiro, Brazil.
Maria Aiza Fontes AndradeDepartment of Pharmacy and Graduate program in Applied Heath Science, Federal University of Sergipe, Lagarto, Sergipe, Brazil.
Luís Cristóvão PortoTIXUS Technologic Core for Tissue Repair and Histocompatibility, Rio de Janeiro State University, Rio de Janeiro, Brazil.
Daniela Santoro RosaDepartment of Microbiology, Immunology and Parasitology, Federal University of Sao Paulo, São Paulo, Brazil.
Rafael Ciro Marques CavalcanteDepartment of Pharmacy and Graduate program in Applied Heath Science, Federal University of Sergipe, Lagarto, Sergipe, Brazil.
Cristiane Bani CorrêaPostgraduate Program in Health Science, Federal University of Sergipe, Aracaju, SE, Brazil.
John SidneyDivision of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, CA, United States.
Alessandro SetteDivision of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, CA, United States.
Roque Pacheco de AlmeidaMolecular Biology Laboratory, University Hospital, Department of Medicine Federal University of Sergipe, Aracaju, Sergipe, Brazil.
Clarisa Beatriz Palatnik-de-SousaInstitute of Microbiology Paulo de Góes, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: No vaccine is currently licensed against human visceral leishmaniasis (VL), a fatal CD4+ T cell immunosupressive disease against which chemotherapy is reduced to a few toxic drugs. The NH36 nucleoside hydrolase is a DNA metabolism vital enzyme present in all Methods: the sequences of HLA-Class I and Class II T cell epitopes were predicted in the NH36 peptide sequence using the Tepitope, Propred, IEDB and NetMHCpan EL 4.1 immune informatic tools. The epitopes were synthetized and used to study their reactivity with sera samples, and to stimulate the Results: We identified Discussion: Both MultiAAA and MultiGPGPG proteins could be potentially used for universal human vaccination against leishmaniasis.

Indexed as

Antigens, ProtozoanEpitopes, T-LymphocyteHLA AntigensLeishmaniasis VaccinesLeishmaniasis, VisceralCD4-Positive T-LymphocytesCytokinesHumansVaccine DevelopmentAntigens, ProtozoanCytokinesEpitopes, T-LymphocyteHLA AntigensLeishmaniasis VaccinesHLA class I and class II promiscuous epitopesLeishmania conserved antigensleishmaniosismultiepitope based vaccinesvisceral leishmaniosis

Identifiers

PMID40230841
PMCPMC11994619

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.